These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
645 related articles for article (PubMed ID: 34449792)
1. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. Lapp SA; Edara VV; Lu A; Lai L; Hussaini L; Chahroudi A; Anderson LJ; Suthar MS; Anderson EJ; Rostad CA PLoS One; 2021; 16(8):e0256482. PubMed ID: 34449792 [TBL] [Abstract][Full Text] [Related]
2. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033 [TBL] [Abstract][Full Text] [Related]
3. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples. Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma. Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688 [TBL] [Abstract][Full Text] [Related]
5. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013 [TBL] [Abstract][Full Text] [Related]
6. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679 [TBL] [Abstract][Full Text] [Related]
7. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS. Fierz W; Walz B Front Immunol; 2020; 11():1120. PubMed ID: 32582200 [TBL] [Abstract][Full Text] [Related]
8. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155 [TBL] [Abstract][Full Text] [Related]
10. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. Padoan A; Bonfante F; Cosma C; Di Chiara C; Sciacovelli L; Pagliari M; Bortolami A; Costenaro P; Musso G; Basso D; Giaquinto C; Plebani M Clin Chem Lab Med; 2021 Jul; 59(8):1444-1452. PubMed ID: 33855843 [TBL] [Abstract][Full Text] [Related]
11. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172 [TBL] [Abstract][Full Text] [Related]
12. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers. Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480 [TBL] [Abstract][Full Text] [Related]
13. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991 [TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Dispinseri S; Secchi M; Pirillo MF; Tolazzi M; Borghi M; Brigatti C; De Angelis ML; Baratella M; Bazzigaluppi E; Venturi G; Sironi F; Canitano A; Marzinotto I; Tresoldi C; Ciceri F; Piemonti L; Negri D; Cara A; Lampasona V; Scarlatti G Nat Commun; 2021 May; 12(1):2670. PubMed ID: 33976165 [TBL] [Abstract][Full Text] [Related]
15. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Sampson AT; Heeney J; Cantoni D; Ferrari M; Sans MS; George C; Di Genova C; Mayora Neto M; Einhauser S; Asbach B; Wagner R; Baxendale H; Temperton N; Carnell G Viruses; 2021 Aug; 13(8):. PubMed ID: 34452443 [TBL] [Abstract][Full Text] [Related]
16. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194 [TBL] [Abstract][Full Text] [Related]
17. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). Anderson EM; Diorio C; Goodwin EC; McNerney KO; Weirick ME; Gouma S; Bolton MJ; Arevalo CP; Chase J; Hicks P; Manzoni TB; Baxter AE; Andrea KP; Burudpakdee C; Lee JH; Vella LA; Henrickson SE; Harris RM; Wherry EJ; Bates P; Bassiri H; Behrens EM; Teachey DT; Hensley SE J Pediatric Infect Dis Soc; 2021 May; 10(5):669-673. PubMed ID: 33263756 [TBL] [Abstract][Full Text] [Related]
18. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals. Adami FL; de Castro MV; Almeida BDS; Daher IP; Yamamoto MM; Souza Santos K; Zatz M; Naslavsky MS; Rosa DS; Cunha-Neto E; de Oliveira VL; Kalil J; Boscardin SB Front Immunol; 2024; 15():1396603. PubMed ID: 38846944 [TBL] [Abstract][Full Text] [Related]
19. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020. Sermet-Gaudelus I; Temmam S; Huon C; Behillil S; Gajdos V; Bigot T; Lurier T; Chrétien D; Backovic M; Delaunay-Moisan A; Donati F; Albert M; Foucaud E; Mesplées B; Benoist G; Faye A; Duval-Arnould M; Cretolle C; Charbit M; Aubart M; Auriau J; Lorrot M; Kariyawasam D; Fertitta L; Orliaguet G; Pigneur B; Bader-Meunier B; Briand C; Enouf V; Toubiana J; Guilleminot T; van der Werf S; Leruez-Ville M; Eloit M Euro Surveill; 2021 Apr; 26(13):. PubMed ID: 33797390 [TBL] [Abstract][Full Text] [Related]
20. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]